These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33512760)

  • 1. Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis.
    Ehx G; Ritacco C; Hannon M; Dubois S; Delens L; Willems E; Servais S; Drion P; Beguin Y; Baron F
    Am J Transplant; 2021 Aug; 21(8):2662-2674. PubMed ID: 33512760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism.
    Foley JE; Jung U; Miera A; Borenstein T; Mariotti J; Eckhaus M; Bierer BE; Fowler DH
    J Immunol; 2005 Nov; 175(9):5732-43. PubMed ID: 16237064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin-based graft-versus-host disease prophylaxis increases the immunosuppressivity of myeloid-derived suppressor cells without affecting T cells and anti-tumor cytotoxicity.
    Scheurer J; Reisser T; Leithäuser F; Messmann JJ; Holzmann K; Debatin KM; Strauss G
    Clin Exp Immunol; 2020 Dec; 202(3):407-422. PubMed ID: 32681646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of mTOR Inhibition with Sirolimus on Natural Killer Cell Reconstitution in Allogeneic Stem Cell Transplantation.
    Haroun-Izquierdo A; Lanuza PM; Pfefferle A; Netskar H; Ask EH; Törlén J; Björklund A; Sohlberg E; Malmberg KJ
    Transplant Cell Ther; 2023 Jun; 29(6):376.e1-376.e11. PubMed ID: 36966873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
    Fowler DH; Mossoba ME; Steinberg SM; Halverson DC; Stroncek D; Khuu HM; Hakim FT; Castiello L; Sabatino M; Leitman SF; Mariotti J; Gea-Banacloche JC; Sportes C; Hardy NM; Hickstein DD; Pavletic SZ; Rowley S; Goy A; Donato M; Korngold R; Pecora A; Levine BL; June CH; Gress RE; Bishop MR
    Blood; 2013 Apr; 121(15):2864-74. PubMed ID: 23426943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin-resistant effector T-cell therapy.
    Fowler DH
    Immunol Rev; 2014 Jan; 257(1):210-25. PubMed ID: 24329799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity.
    Vaeth M; Bäuerlein CA; Pusch T; Findeis J; Chopra M; Mottok A; Rosenwald A; Beilhack A; Berberich-Siebelt F
    Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1125-30. PubMed ID: 25583478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
    Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
    Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-12hi rapamycin-conditioned dendritic cells mediate IFN-γ-dependent apoptosis of alloreactive CD4+ T cells in vitro and reduce lethal graft-versus-host disease.
    Stenger EO; Rosborough BR; Mathews LR; Ma H; Mapara MY; Thomson AW; Turnquist HR
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):192-201. PubMed ID: 24239650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
    Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
    Front Immunol; 2020; 11():181. PubMed ID: 32117306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation.
    Rodriguez N; Lee J; Flynn L; Murray F; Devlin SM; Soto C; Cho C; Dahi P; Giralt S; Perales MA; Sauter C; Ponce DM
    Transplant Cell Ther; 2021 Nov; 27(11):920.e1-920.e9. PubMed ID: 34029766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression.
    Miller WP; Srinivasan S; Panoskaltsis-Mortari A; Singh K; Sen S; Hamby K; Deane T; Stempora L; Beus J; Turner A; Wheeler C; Anderson DC; Sharma P; Garcia A; Strobert E; Elder E; Crocker I; Crenshaw T; Penedo MC; Ward T; Song M; Horan J; Larsen CP; Blazar BR; Kean LS
    Blood; 2010 Dec; 116(24):5403-18. PubMed ID: 20833977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing anti-T-lymphocyte globulin dosing to improve long-term outcome after unrelated hematopoietic cell transplantation for hematologic malignancies.
    Turki AT; Klisanin V; Bayraktar E; Kordelas L; Trenschel R; Ottinger H; Steckel NK; Tsachakis-Mück N; Leserer S; Ditschkowski M; Liebregts T; Koldehoff M; Fleischhauer K; Beelen DW
    Am J Transplant; 2020 Mar; 20(3):677-688. PubMed ID: 31597002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of human regulatory T cells de novo with suppressive function prevent xenogeneic graft versus host disease.
    Qian X; Wang K; Wang X; Zheng SG; Lu L
    Int Immunopharmacol; 2011 May; 11(5):630-7. PubMed ID: 21147213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.
    Nakamae H; Nakane T; Okamura H; Koh H; Nakashima Y; Hirose A; Nakamae M; Nishimoto M; Kuno M; Makuuchi Y; Harada N; Takakuwa T; Hino M
    Int J Hematol; 2022 Jan; 115(1):77-86. PubMed ID: 34586587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.